## 3 Results  
Baseline characteristics comparison between the two treatment groups was presented in Table 1. There were no significant differences in baseline characteristics between the two groups except for gender since there were more male patients in the IVA/PDT group than those in the IVR/PDT group. Figure 1 showed the changes of BCVA of the two groups. The mean logMAR BCVA in the IVA/PDT group significantly improved from 0.73 \(\pm\) 0.65 prior to the initial treatment to 0.60 \(\pm\) 0.69 at 6 months (\(p\) = 0.045), 0.51 \(\pm\) 0.59 at 12 months (\(p\) = 0.010), 0.58 \(\pm\) 0.61 at 18 months (\(p\) = 0.021), and 0.55 \(\pm\) 0.52 at 24 months (\(p\) = 0.022) after the treatment. In the IVR/PDT group, the mean logMAR BCVA significantly improved from 0.76 \(\pm\) 0.64 at \begin{table}
\begin{tabular}{c c c c} \hline \hline  & **IVA/PDT (n = 30)** & **IVR/PDT (n = 25)** & \(p\) **Value** \\ \hline Age (year) & 65.5 \(\pm\) 12.8 & 62.3 \(\pm\) 14.0 & 0.381 \\ \hline Gender (male \%) & 76.7\% & 24.0\% & \textless{}0.001 \\ \hline Lens status (phakic \%) & 66.7\% & 80.0\% & 0.269 \\ \hline Baseline BCVA (LogMAR) & 0.73 \(\pm\) 0.65 & 0.76 \(\pm\) 0.64 & 0.866 \\ \hline Baseline CRT (\(\upmu\)m) & 339 \(\pm\) 96 & 302 \(\pm\) 59 & 0.090 \\ \hline \end{tabular}
\end{table} 
Table 1: Baseline characteristics of patients in two treatment groups. baseline to 0.53 \(\pm\) 0.64 at 6 months (\(p\) = 0.008) and 0.48 \(\pm\) 0.55 at 12 months (\(p\) = 0.015), but the BCVA changed to 0.59 \(\pm\) 0.65 at 18 months (\(p\) = 0.113) and 0.61 \(\pm\) 0.69 at 24 months (\(p\) = 0.256) insignificantly when compared to baseline BCVA. There were no significant differences in change of BCVA between the two groups at every 6-month visit. At the 24-month follow-up, BCVA gain \(\geq\) 0.3 LogMAR was achieved in 23.3% and 40.0% patients of IVA/PDT and IVR/PDT, respectively. BCVA loss \(\geq\) 0.3 LogMAR was recorded in 6.7% and 24.0% of patients in IVA/PDT and IVR/PDT groups, respectively. There were no significant differences in BCVA gain or BCVA loss \(\geq\) 0.3 LogMAR between the two groups (Table 2). The CRT decreased significantly from 339 \(\pm\) 96 \(\upmu\)m at baseline to 228 \(\pm\) 44 \(\upmu\)m at 24-month in IVA/PDT, and from 302 \(\pm\) 59 \(\upmu\)m at baseline to 209 \(\pm\) 38 \(\upmu\)m at 24-month in IVR/PDT. Figure 2 shows the changes of CRT of the two groups, which were significantly reduced at every 6-month visit compared to baseline in both groups (\(p\) < 0.001) except for \begin{table}
\begin{tabular}{c c c c} \hline \hline  & **IVA/PDT (n = 30)** & **IVR/PDT (n = 25)** & \(p\)**Value** \\ \hline BCVA gain \(\geq\) 0.3 LogMAR & 23.3\% & 40.0\% & 0.183 \\ \hline BCVA loss \(\geq\) 0.3 LogMAR & 6.7\% & 24.0\% & 0.069 \\ \hline
3-month complete polyp regression rate & 53.3\% & 52.0\% & 0.921 \\ \hline
6-month dry macula rate & 93.3\% & 72.0\% & 0.033 \\ \hline
12-month dry macula rate & 96.7\% & 96.0\% & 0.895 \\ \hline
18-month dry macula rate & 96.7\% & 80.0\% & 0.048 \\ \hline
24-month dry macula rate & 96.7\% & 92.0\% & 0.448 \\ \hline Retreatment & 26.7\% & 60.0\% & 0.013 \\ \hline Additional IVI monotherapy (times) & 0.13 \(\pm\) 0.35 & 0.68 \(\pm\) 0.85 & 0.005 \\ \hline Additional combination therapy (times) & 0.23 \(\pm\) 0.43 & 0.52 \(\pm\) 0.59 & 0.048 \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Outcome and retreatment comparison between two groups. Figure 1: Change in mean best-corrected visual acuity (BCVA) in LogMAR (\({}^{\star}\)\(p\) < 0.05). the 18-month follow-up in the IVR/PDT group (\(p\) = 0.092). The change in CRT did not differ between the two groups at every 6-month visit. Complete polyp regression rate at 3-month was 53.3% in the IVA/PDT group, and 52.0% in the IVR/PDT group. Between the two groups, the complete polyp regression rate did not differ (\(p\) = 0.921). In the IVA/PDT group, the dry macula rate was 93.3% at 6 months, and then maintained at 96.7% at the 12-month, 18-month, and 24-month period.